Protein losing enteropathy: Difference between revisions
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Protein losing [[enteropathy]] is the loss of plasma proteins from the gastrointestinal tract caused by an array of abnormalities | [[Protein]] losing [[enteropathy]] is the loss of [[plasma proteins]] from the [[gastrointestinal tract]] caused by an array of abnormalities. | ||
==Historical Perspective== | ==Historical Perspective== | ||
| Line 25: | Line 25: | ||
==Pathophysiology== | ==Pathophysiology== | ||
Normally there is a balance between the synthesis and degradation of [[proteins]] maintained by a series of interconnected processes in the body. Any condition which disrupts the normal protein [[stasis]] where the loss of protein through the [[gastrointestinal tract]] exceeds the body’s ability to synthesize proteins failing to compensate for the loss leads to the development of a state of low serum protein called [[hypoproteinemia]]. <ref name="WaldmannWochner1969">{{cite journal|last1=Waldmann|first1=T.A.|last2=Wochner|first2=R.D.|last3=Strober|first3=W.|title=The role of the gastrointestinal tract in plasma protein metabolism|journal=The American Journal of Medicine|volume=46|issue=2|year=1969|pages=275–285|issn=00029343|doi=10.1016/0002-9343(69)90011-4}}</ref> | Normally there is a balance between the [[synthesis]] and [[degradation]] of [[proteins]] maintained by a series of interconnected processes in the body. Any condition which disrupts the normal protein [[stasis]] where the loss of [[protein]] through the [[gastrointestinal tract]] exceeds the body’s ability to synthesize [[Protein|proteins]] failing to compensate for the loss leads to the development of a state of low serum protein called [[hypoproteinemia]]. <ref name="WaldmannWochner1969">{{cite journal|last1=Waldmann|first1=T.A.|last2=Wochner|first2=R.D.|last3=Strober|first3=W.|title=The role of the gastrointestinal tract in plasma protein metabolism|journal=The American Journal of Medicine|volume=46|issue=2|year=1969|pages=275–285|issn=00029343|doi=10.1016/0002-9343(69)90011-4}}</ref> | ||
*Primary [[gastrointestinal]] diseases such as [[inflammatory bowel disease]] and [[malignancies]] initiates a series of abnormal changes leading to the disruption of the protective [[mucosal layer]] of the gut resulting in [[inflammation]], [[erosions]] and [[ulcerations]] of the normal [[mucosa]] leading to: | *Primary [[gastrointestinal]] diseases such as [[inflammatory bowel disease]] and [[malignancies]] initiates a series of abnormal changes leading to the disruption of the protective [[mucosal layer]] of the [[gut]] resulting in [[inflammation]], [[erosions]] and [[ulcerations]] of the normal [[mucosa]] leading to: | ||
**Alteration in the [[mucosal]] lining of the [[gut]]. | **Alteration in the [[mucosal]] lining of the [[gut]]. | ||
**An increase in the permeability for the previously [[Semi-permeable membrane|semi-permeable]] and non-permeable [[proteins]], leading to excessive protein leakage through [[gastrointestinal tract]]. | **An increase in the [[permeability]] for the previously [[Semi-permeable membrane|semi-permeable]] and non-permeable [[proteins]], leading to excessive [[protein]] leakage through [[gastrointestinal tract]]. | ||
**Decrease surface area for protein reabsorption leading to poor reabsorption. | **Decrease surface area for [[protein]] [[reabsorption]] leading to poor [[reabsorption]]. | ||
*Non-erosive [[gastrointestinal]] conditions such as [[connective tissue disorders]] and [[infectious diseases]] affecting the [[mucosa]] of the [[gastrointestinal tract]] causes the leakage of [[proteins]] into the [[lumen]] of [[gastrointestinal tract]] in a similar manner as erosive [[gastrointestinal diseases]]. | *Non-erosive [[gastrointestinal]] conditions such as [[connective tissue disorders]] and [[infectious diseases]] affecting the [[mucosa]] of the [[gastrointestinal tract]] causes the leakage of [[proteins]] into the [[lumen]] of [[gastrointestinal tract]] in a similar manner as erosive [[gastrointestinal diseases]]. | ||
*Conditions leading to [[lymphatic obstruction]] such as [[lymphomas]] and other [[benign]] or [[malignant]] masses causes an increase in the pressure inside the [[lymphatic system]] which forces the [[lymph]] to leak out of the [[lymphatic vessels]] into the [[lumen]] of [[gastrointestinal tract]] leading to protein loss. <ref name="pmid30762910">{{cite journal| author=Craven MD, Washabau RJ| title=Comparative pathophysiology and management of protein-losing enteropathy. | journal=J Vet Intern Med | year= 2019 | volume= 33 | issue= 2 | pages= 383-402 | pmid=30762910 | doi=10.1111/jvim.15406 | pmc=6430879 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30762910 }} </ref> | *Conditions leading to [[lymphatic obstruction]] such as [[lymphomas]] and other [[benign]] or [[malignant]] masses causes an increase in the pressure inside the [[lymphatic system]] which forces the [[lymph]] to leak out of the [[lymphatic vessels]] into the [[lumen]] of [[gastrointestinal tract]] leading to protein loss. <ref name="pmid30762910">{{cite journal| author=Craven MD, Washabau RJ| title=Comparative pathophysiology and management of protein-losing enteropathy. | journal=J Vet Intern Med | year= 2019 | volume= 33 | issue= 2 | pages= 383-402 | pmid=30762910 | doi=10.1111/jvim.15406 | pmc=6430879 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30762910 }} </ref> | ||
Revision as of 15:08, 15 February 2021
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Synonyms and keywords: Protein loss, protein deficiency, GI protein loss, gastrointestinal protein loss, protein-losing gastroenteropathy, protein-losing gastroenteropathy, gastroenteropathy, gastric protein loss, helicobacter pylori, H pylori, giant hypertrophic gastropathy, menetrier disease, ménétrier, disease, loss of plasma proteins from the gastrointestinal tract, excessive leakage of plasma proteins into the lumen of the gastrointestinal tract, lymphatic obstruction, mucosal disease with erosions, ulcerations, swelling of the legs, peripheral edema, decreased plasma oncotic pressure
Overview
Protein losing enteropathy is the loss of plasma proteins from the gastrointestinal tract caused by an array of abnormalities.
Historical Perspective
- [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
- In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
- In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
Classification
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [group1]
- [group2]
- [group3]
- Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3]
Pathophysiology
Normally there is a balance between the synthesis and degradation of proteins maintained by a series of interconnected processes in the body. Any condition which disrupts the normal protein stasis where the loss of protein through the gastrointestinal tract exceeds the body’s ability to synthesize proteins failing to compensate for the loss leads to the development of a state of low serum protein called hypoproteinemia. [1]
- Primary gastrointestinal diseases such as inflammatory bowel disease and malignancies initiates a series of abnormal changes leading to the disruption of the protective mucosal layer of the gut resulting in inflammation, erosions and ulcerations of the normal mucosa leading to:
- Alteration in the mucosal lining of the gut.
- An increase in the permeability for the previously semi-permeable and non-permeable proteins, leading to excessive protein leakage through gastrointestinal tract.
- Decrease surface area for protein reabsorption leading to poor reabsorption.
- Non-erosive gastrointestinal conditions such as connective tissue disorders and infectious diseases affecting the mucosa of the gastrointestinal tract causes the leakage of proteins into the lumen of gastrointestinal tract in a similar manner as erosive gastrointestinal diseases.
- Conditions leading to lymphatic obstruction such as lymphomas and other benign or malignant masses causes an increase in the pressure inside the lymphatic system which forces the lymph to leak out of the lymphatic vessels into the lumen of gastrointestinal tract leading to protein loss. [2]
Causes
Most cases of protein losing enteropathy are caused as a result of:
- Primary gastrointestinal disorders
- Lymphatic obstruction
Primary Gastrointestinal Diseases
Mucosal Erosions/Ulcerations
Primary gastrointestinal diseases causing erosion or ulceration of the mucosa of the gut leading to fecal loss of proteins such as:[4][5]
- Inflammatory bowel diseases (Crohn disease, Ulcerative colitis)
- Malignancies involving the gut mucosa
- Graft vs. host disease
- Esophageal and gastric erosions or ulcerations
- Carcinoid syndrome
- Bacterial infection with Clostridium difficile causing pseudomembranous colitis
- Parasitic infection with Giardia
Non-Erosive/Ulcerative Mucosal involvement
- Celiac disease
- Eosinophilic gastritis
- Hypertrophic gastritis
- Connective tissue disorders: Systemic lupus erythematosus
- Cutaneous burns[6]
Lymphatic Obstruction
Conditions responsible for causing lymphatic obstruction leading to the leakage of lymph into the lumen of gut such as:
- Lymphoma
- Congenital or acquired lymphatic diseases
- Lymphatic filariasis
- Sarcoidosis
- Cardiovascular diseases: Congestive heart failure, Restrictive pericarditis
- Intestinal Tuberculosis
- Fortan surgical procedure
- Cirrhosis with portal hypertension
- Retroperitoneal fibrosis[7] [8] [9]
Complete Differential Diagnosis Of Underlying Causes
- Acute gastroenteritis
- AIDS
- Allergic Gastroenteritis
- Amyloidosis
- Angioedema
- Bacterial overgrowth
- Carcinoid Syndrome
- Celiac Sprue
- Clostridium Difficile
- Congestive Heart Failure
- Connective tissue disorders
- Constrictive pericarditis
- Crohn's Disease
- Duodenal erosions or ulcerations
- Esophageal erosions or ulcerations
- Graft vs. Host Disease
- Henoch-Schonlein Purpura
- Idiopathic ulcerative jejunoileitis
- Intestinal endometriosis
- Intestinal parasites
- Kaposi Sarcoma
- Lymphoenteric fistula
- Lymphoma
- Menetrier's Disease
- Microscopic colitis
- Mucosal-based neoplasm
- Neurofibromatosis
- Protein dyscrasia
- Pseudomembranous colitis
- Retroperitoneal fibrosis
- Sarcoidosis
- Stomach (erosions, ulcerations)
- Tropical sprue
- Tuberculosis
- Ulcerative Colitis
- Whipple's Disease
Diagnosis
As hypoproteinemia is the key factor in evaluating a patient for protein losing enteropathy, other common causes of hypoproteinemia such as nephrotic syndrome, impaired protein synthesis due to chronic liver disease and malnutrition must be excluded first.[10]
Laboratory Studies
As the most prominent laboratory finding is a decrease in serum concentration of albumin and globulin, the diagnostic work up protein losing enteropathy consist of quantitative measurements of Alpha-1 antitrypsin or 51Cr-albumin.[11]
- Alpha-1 antitrypsin (A1AT) used as an endogenous marker is a sensitive and inexpensive laboratory test performed to diagnose protein losing enteropathy and has become the current standard for quantitating protein losing enteropathy.[12] Measurement of fecal volume and fecal loss of alpha-1 antitrypsin depicts the plasma concentration of alpha-1 antitrypsin as;
Alpha 1-AT plasma concentration = ((stool volume) x (stool alpha 1-AT)) / (serum alpha-1 AT)
Gastrointestinal loss of alpha-1 antitrypsin is measured in feces and a clearance greater than 27mL/day is considered diagnostic for protein losing enteropathy.[13]
- 51Cr-labeled albumin can also be measured followed by stool collection to determine the amount of protein loss into the gastrointestinal tract.
Imaging Studies
Following the detection of abnormal amounts of alpha-1 antitrypsin in the stool, the following tests can be performed to detect the specific etiology for the protein loss into the gastrointestinal lumen.[11]
- Administration of technetium-99 labeled macromolecules such as albumin. Imaging is required to localize the primary site of protein leakage with no requirement for fecal collection. Scintigraphy is becoming popular in the diagnosis and localization of the site of protein leakage.
- For the diagnosis of lymphatic obstruction, computed tomography, lymphangiography or magnetic resonance imaging can be used.
- Radiographic contrast studies and endoscopy can be performed to evaluate the ulcerative or erosive gastrointestinal causes of the protein loss.
- For detecting cardiac diseases causing loss of protein, echocardiography or radionuclide scanning of the heart can be performed.
Other tests:
- All patients should undergo basic laboratory tests such as complete blood test, liver and renal function tests.
- Work up for autoimmune diseases such as systemic lupus erythematosus should be ordered if there is a suspicion of connective tissue disorder causing protein loss in the gastrointestinal tract.
- Biopsy samples of the mucosa and stool cultures for ova and parasites should be performed if there is a suspicion of ulcerative or erosive gastrointestinal disease and parasitic infection, respectively.
Treatment
Protein losing enteropathy is not a separate disease entity but a complication of different pathological conditions and hence treatment depends upon the underlying etiology of the disease causing protein losing enteropathy as a complication. For instance, if the underlying pathology involves inflammation or autoimmune condition such as; inflammatory bowel disease or connective tissue disorder, the mainstay of treatment will be to treat the underlying pathology with immunosuppressive medications. [14]
References
- ↑ Waldmann, T.A.; Wochner, R.D.; Strober, W. (1969). "The role of the gastrointestinal tract in plasma protein metabolism". The American Journal of Medicine. 46 (2): 275–285. doi:10.1016/0002-9343(69)90011-4. ISSN 0002-9343.
- ↑ Craven MD, Washabau RJ (2019). "Comparative pathophysiology and management of protein-losing enteropathy". J Vet Intern Med. 33 (2): 383–402. doi:10.1111/jvim.15406. PMC 6430879. PMID 30762910.
- ↑ Craven, Melanie D.; Washabau, Robert J. (2019). "Comparative pathophysiology and management of protein‐losing enteropathy". Journal of Veterinary Internal Medicine. 33 (2): 383–402. doi:10.1111/jvim.15406. ISSN 0891-6640.
- ↑ Akkelle BS, Tutar E, Sengul OK, Celikel CA, Ertem D (2018). "A Rare Complication of Giardiasis in Children: Protein-losing Enteropathy". Pediatr Infect Dis J. 37 (12): e345–e347. doi:10.1097/INF.0000000000002025. PMID 30408010.
- ↑ Zubiaga Toro L, Ruiz-Tovar J, Castro MJ, Ortiz de Solórzano FJ, Luque de León E, Jiménez JM; et al. (2019). "Whipple disease after bariatric surgery: from malabsorption to malnutrition status". Nutr Hosp. 36 (1): 238–241. doi:10.20960/nh.02258. PMID 30834767.
- ↑ Venkatesh, Balasubramanian; Gough, Jenny; Ralston, David R.; Muller, Michael; Pegg, Stuart (2004). "Protein losing enteropathy in critically ill adult patients with burns: a preliminary report". Intensive Care Medicine. 30 (1): 162–166. doi:10.1007/s00134-003-2050-2. ISSN 0342-4642.
- ↑ Furfaro F, Bezzio C, Maconi G (2015). "Protein-losing enteropathy in inflammatory bowel diseases". Minerva Gastroenterol Dietol. 61 (4): 261–5. PMID 26446687.
- ↑ Amiot A (2015). "[Protein-losing enteropathy]". Rev Med Interne. 36 (7): 467–73. doi:10.1016/j.revmed.2014.12.001. PMID 25618488.
- ↑ "StatPearls". 2020. PMID 31194423.
- ↑ Umar, Sarah B; DiBaise, John K (2010). "Protein-Losing Enteropathy: Case Illustrations and Clinical Review". American Journal of Gastroenterology. 105 (1): 43–49. doi:10.1038/ajg.2009.561. ISSN 0002-9270.
- ↑ 11.0 11.1 Levitt, David; Levitt, Michael (2017). "Protein losing enteropathy: comprehensive review of the mechanistic association with clinical and subclinical disease states". Clinical and Experimental Gastroenterology. Volume 10: 147–168. doi:10.2147/CEG.S136803. ISSN 1178-7023.
- ↑ Karbach U, Ewe K (1989). "Enteric protein loss in various gastrointestinal diseases determined by intestinal alpha 1-antitrypsin clearance". Z Gastroenterol. 27 (7): 362–5. PMID 2475983.
- ↑ Florent C, L'Hirondel C, Desmazures C, Aymes C, Bernier JJ (1981). "Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy". Gastroenterology. 81 (4): 777–80. PMID 6973500.
- ↑ "StatPearls". 2020. PMID https://www.ncbi.nlm.nih.gov/pubmed/31194423 Check
|pmid=value (help).